✓ Translated by DotMD AI Clinical Council Source: Arthritis research & therapy • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #41372962 ↗

Phase III Randomized Trial: A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial

Original Paper Title: “A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • CONCLUSION: Our composite biomarker score showed a moderate cross-sectional correlation with mRSS and potentially complement mRSS in the assessment of skin activity. The differential variations for serum COL4A1 across treatment groups warrant further evaluation as a predictive marker of immunotherapeutic response in dcSSc.
  • Study Design & Sample: Phase III Randomized Trial published in Arthritis research & therapy (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Arthritis research & therapy (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: BACKGROUND: Skin fibrosis is a cardinal manifestation of systemic sclerosis (SSc) and is routinely measured by modified Rodnan skin score (mRSS), which is however limited by its operator-dependence and may not reflect the complex disease biology at the cutaneous compartment. Key clinical takeaway: CONCLUSION: Our composite biomarker score showed a moderate cross-sectional correlation with mRSS and potentially complement mRSS in the assessment of skin activity. The differential variations for serum COL4A1 across treatment groups warrant...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Arthritis research & therapy, 2025-12-10; Phase III Randomized Trial; Rigor 82/100): CONCLUSION: Our composite biomarker score showed a moderate cross-sectional correlation with mRSS and potentially complement mRSS in the assessment of skin activity. The differential variations for serum COL4A1 across treatment groups warrant further evaluation as a predictive marker of immunotherapeutic response in dcSSc.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: scleroderma → Condition: rheumatoid-arthritis-without-rheumatoid-factor-unspecified-site → Condition: rheumatoid-arthritis-without-rheumatoid-factor-vertebrae →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41372962: Phase III Randomized Trial: A composite biomarker score to predict modified Rodnan skin score in systemic sclerosis: insight from autologous stem cell transplantation international scleroderma trial

3 of 3 Free Questions Remaining